Acorn Capital Advisors, LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), Acorn Capital Advisors, LLC reported 21 stock positions worth $152.9 million. Its top holding was CG Oncology (CGON) at 19.2% of the portfolio, followed by Urogen Pharma (URGN, 11.3%) and Y-Mabs Therapeutics (YMAB, 10.1%). Compared with Q1 2025, it sold out of 1, added to 7 and reduced 5. The biggest buy was Puma Biotechnology (PBYI, shares +5%) and the biggest sale an exit from Optinose.
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0002054410
- Portfolio Value
- $152.9M (Q2 2025)
- SEC Filing
- 0001636587-25-000043 ↗ filed Aug 14, 2025
Holdings Value
Holdings 21 stocks · $152.9M
| CGON CG Oncology Inc. | 19.24% | 1,131,501 | $29.4M | No change |
| URGN Urogen Pharma Ltd. | 11.29% | 1,259,749 | $17.3M | Reduce -16.9% |
| YMAB Y-Mabs Therapeutics Inc. | 10.09% | 3,418,995 | $15.4M | Add +5.7% |
| PBYI Puma Biotechnology Inc. | 9.27% | 4,131,299 | $14.2M | Add +4.8% |
| CADL Candel Therapeutics Inc. | 8.54% | 2,580,517 | $13.1M | Add +19.9% |
| TRVI Trevi Therapeutics Inc. | 7.67% | 2,144,844 | $11.7M | No change |
| TERN Terns Pharmaceuticals Inc. | 4.81% | 1,971,264 | $7.4M | No change |
| OKUR Onkure Therapeutics Inc. Class A | 4.44% | 2,839,674 | $6.8M | Add +97.2% |
| HELP Cybin Inc. | 4.03% | 734,394 | $6.2M | No change |
| BCAX Bicara Therapeutics Inc. | 3.91% | 643,382 | $6.0M | No change |
| TARA Protara Therapeutic Inc. | 3.47% | 1,752,115 | $5.3M | Add +36.9% |
| CRDF Cardiff Oncology Inc. | 2.90% | 1,408,767 | $4.4M | Reduce -2.3% |
| AURA Aura Biosciences Inc. | 2.44% | 595,744 | $3.7M | Add +0.9% |
| VSTM Verastem Inc. | 2.12% | 779,498 | $3.2M | No change |
| WHWK Whitehawk Therapeutics Inc. | 1.39% | 1,139,363 | $2.1M | No change |
| BCAB Bioatla Inc. | 1.25% | 4,835,111 | $1.9M | Add +19.9% |
| MURA Mural Oncology PLC | 1.06% | 653,779 | $1.6M | Reduce -48.5% |
| VYNE THERAPEUTICS INC | 0.79% | 736,572 | $1.2M | Reduce -6.3% |
| QTTB Q32 Bio Inc. | 0.78% | 803,425 | $1.2M | No change |
| ACRV Acrivon Therapeutics Inc. | 0.32% | 405,237 | $482K | No change |
| XFOR X4 Pharmaceuticals Inc. | 0.19% | 153,730 | $292K | Reduce -97.9% |
Portfolio Sells Q1 2025 → Q2 2025
| OPTINOSE INC | Sold out | 0.00% | −2.59 |
| XFOR X4 Pharmaceuticals Inc. | Reduce -97.9% | 0.19% | −0.98 |
| CRDF Cardiff Oncology Inc. | Reduce -2.3% | 2.90% | −0.12 |
| VYNE THERAPEUTICS INC | Reduce -6.3% | 0.79% | −0.03 |
| MURA Mural Oncology PLC | Reduce -48.5% | 1.06% | −0.01 |
| URGN Urogen Pharma Ltd. | Reduce -16.9% | 11.29% | +0.10 |
Portfolio Buys Q1 2025 → Q2 2025
| PBYI Puma Biotechnology Inc. | Add +4.8% | 9.27% | +1.49 |
| AURA Aura Biosciences Inc. | Add +0.9% | 2.44% | +1.47 |
| OKUR Onkure Therapeutics Inc. Class A | Add +97.2% | 4.44% | +1.02 |
| YMAB Y-Mabs Therapeutics Inc. | Add +5.7% | 10.09% | +0.53 |
| CADL Candel Therapeutics Inc. | Add +19.9% | 8.54% | +0.43 |
| BCAB Bioatla Inc. | Add +19.9% | 1.25% | +0.31 |
| TARA Protara Therapeutic Inc. | Add +36.9% | 3.47% | −0.16 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 20 | $366.5M | CGON, URGN, TRVI, CADL, PBYI |
| Q1 2026 | 22 | $351.8M | TERN, CGON, URGN, PBYI, TRVI |
| Q4 2025 | 21 | $295.1M | TERN, CGON, URGN, TRVI, PBYI |
| Q3 2025 | 20 | $197.0M | CGON, URGN, PBYI, TRVI, TERN |
| Q2 2025 | 21 | $152.9M | CGON, URGN, YMAB, PBYI, CADL |
| Q1 2025Amended | 22 | $149.9M | CGON, URGN, YMAB, TRVI, CADL |
| Q4 2024Amended | 21 | $185.8M | CGON, YMAB, CADL, URGN, PBYI |